The optimal analgesic dose of rofecoxib: Overview of six randomized controlled trials

Journal of the American Dental Association

Volumn 131, Issue 12, 2000, Pages 1729-1737

  Morrison, Briggs W ^a   Fricke, James ^b   Brown, Jean ^c   Yuan, Weiying ^d   Kotey, Paul ^a   Mehlisch, Donald ^e  

^a MERCK RESEARCH LABORATORIES   (United States)

^b PPD Pharmaco   (United States)

^c Jean Brown Associates   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^e Premier Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ENZYME INHIBITOR; IBUPROFEN; ISOENZYME; LACTONE; MEMBRANE PROTEIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; ROFECOXIB; SULFONE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; FEMALE; HUMAN; MALE; MIDDLE AGED; MOLAR TOOTH; NONPARAMETRIC TEST; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSTOPERATIVE PAIN; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TIME; TOOTH EXTRACTION;

ADOLESCENT; ADULT; ANALGESICS, NON-NARCOTIC; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FEMALE; HUMANS; IBUPROFEN; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MOLAR, THIRD; NAPROXEN; PAIN MEASUREMENT; PAIN, POSTOPERATIVE; PROPORTIONAL HAZARDS MODELS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; STATISTICS, NONPARAMETRIC; SULFONES; SURVIVAL ANALYSIS; TIME FACTORS; TOOTH EXTRACTION;

EID: 0034544360     PISSN: 00028177     EISSN: None     Source Type: Journal    
DOI: 10.14219/jada.archive.2000.0119     Document Type: Article

References (27)

1. Forbes JA. Oral surgery. In: Max MB, Portenoy RK, Laska EM, eds. The design of analgesic clinical trials. New York: Raven Press; 1991:347-74.
2. 2, leukotriene B4, and (s)-flurbiprofen following extraction of impacted third molars. Pain 1997;73(3):339-45.
3. Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 1994;4(1):17-23.
4. Smith TJ. Cyclooxygenases as the principal targets for the action of NSAIDs. Rheum Dis Clin North Am 1998;24(3):501-23.
5. DeWitt D. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta 1991;1083(2):121-34.
6. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 1993;11(2):371-86.
7. Kömhoff M, Gröne H-J, Klein T, Seyberth HW, Nüsing RM. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. Am J Physiol 1997;272:F460-8.
8. Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993;268(9):6610-4.
9. O'Neill GP, Mancini JA, Kargman S, et al. Overexpression of human prostaglandin G/H synthase-1 and -2 by recombinant vaccinia virus: inhibition by nonsteroidal anti-inflammatory drugs and biosynthesis of 15-hydroxyeicosatetraenoic acid. Mol Pharmacol 1994;45(2):245-54.
10. Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, Smith WL. Differential inhibition of human prostaglandin endoperoxide H synthases-1 and -2 by nonsteroidal anti-inflammatory drugs. J Pharmaeol Exp Ther 1994;271(2):927-34.
11. Kargman S, Wong E, Greig GM, et al. Mechanism of selective inhibition of human prostaglandin G/H synthase-1 and -2 in intact cells. Biochem Pharmacol 1996;52(7):1113-25.
12. Berg J, Christoph T, Widerna M, Bodenteich A. Isoenzyme-specific cyclooxygenase inhibitors: a whole cell assay system using the human erythroleukemic cell line HEL and the human monocytic cell line Mono Mac 6. J Pharmacol Toxicol Methods 1997;37(4):179-86.
13. Wong E, DeLuca C, Boily C, et al. Characterization of autocrine inducible prostaglandin H synthase-2 (PGHS-2) in human osteosarcoma cells. Inflamm Res 1997;46(2):51-9.
14. Miralpeix M, Camacho M, Lopez-Belmonte J, et al. Selective induction of cyclooxygenase-2 activity in the permanent human endothelial cell line HUV-EC-C: biochemical and pharmacological characterization. Br J Pharmacol 1997;121(2):171-80.
15. Ehrich EW, Dallob A, De Lepeleire I, et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999;65(3): 336-47.
16. Morrison BW, Christensen S, Yuan W, Brown J, Amlani S, Seidenberg B. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther 1999;21(6):943-53.
17. Morrison BW, Daniels SE, Kotey P, Cantu N, Seidenberg B. Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. Obstet Gynecol 1999;94(4):504-8.
18. Mehlisch DR, Fulmer RI. A crossover comparison of bromfenac sodium, naproxen sodium, and placebo for relief of pain from primary dysmenorrhea. J Womens Health 1997;6(1):83-92.
19. Cox DR. Regression models and life-tables. J Royal Stat Soc (series B) 1972;34: 187-220.
20. Ehrich E, Schnitzer T, McIlwain H, et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: a 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheum 1999;26(11):2438-47.
21. Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Arthritis Rheum 2000;43:978-87.
22. Saag K, van der Heijde D, Fisher C, et al. Rofecoxib, a new COX-2 selective NSAID shows sustained efficacy, comparable to NSAIDs, in a six week and a one year trial in patients with osteoarthritis. Arch Fam Med (in press).
23. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;117:776-83.
24. Hawkey C, Laine L, Simon T, et al. Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, controlled, double-blind, placebo-controlled trial. Arthritis Rheum 2000;43:370-7.
25. Langman MJ, Jensen DM, Watson DJ, et al. Incidence of upper gastrointestinal perforations, symptomatic ulcers, bleeding (PUBs): rofecoxib compared to NSAIDs. JAMA 1999;282:1929-33.
26. Merck & Co. Inc. Rofecoxib prescribing information. West Point, Pa.
27. Physicians' desk reference. 54th ed. Montvale, N.J.: Medical Economics; 2000:1912-5.